T. Rowe Price Investment Management, Inc. Nuvalent, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Nuvalent, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,094,568 shares of NUVL stock, worth $83.9 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
1,094,568
Previous 450,774
142.82%
Holding current value
$83.9 Million
Previous $32 Million
161.24%
% of portfolio
0.05%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding NUVL
# of Institutions
226Shares Held
59.5MCall Options Held
277KPut Options Held
255K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.38 Billion31.57% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$404 Million18.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$347 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$232 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$138 Million0.02% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.29B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...